M&A Advisory in Minnesota
Minnesota's Medical Alley — 530+ device establishments at 4x the national labor concentration — drove the state's largest 2025 M&A wave: Solventum's $4.0B Thermo Fisher divestiture, Medtronic's $550M Scientia Vascular tuck-in, and Ecolab's $4.75B CoolIT acquisition, all anchored in the Twin Cities.
Minnesota's M&A Economy
Minnesota sits at the intersection of unmatched Fortune 500 density and a world-leading medtech ecosystem — 15 Fortune 500 HQs including UnitedHealth ($372B revenue), 3M/Solventum, Target, and US Bancorp, combined with Medical Alley's 530+ medical device establishments employing 34,520+ workers at over 4x the national labor concentration. State GDP reached $531.5B nominal in 2025 (BEA), ranking Minnesota among the top 20 state economies in the US. An estimated 14,000–16,000 LMM-eligible businesses operate statewide, with over 50% of owner-operators aged 55+ and fewer than 30% holding written succession plans — creating a sustained sell-side pipeline through 2030. Twin Cities PE dry powder from resident sponsors (Norwest Equity Partners, Goldner Hawn, ShoreView, Tonka Bay, Castlelake, Värde Partners) exceeds $10B regionally. GF Data tracked TEV/EBITDA at 7.2x for H1 2025 LMM closes nationally, with $5M–$8M EBITDA Minnesota deals clearing 6.0x–7.5x and $10M+ EBITDA businesses commanding 8.0x–10.0x. The primary headwind: Minnesota's 9.8% corporate franchise tax is the highest in the US, ranking 44th on the Tax Foundation's 2026 State Competitiveness Index — making entity structure and pre-sale planning critical to maximizing after-tax proceeds for Minnesota sellers.
Minnesota at a Glance
Key Markets in Minnesota
Minneapolis-St. Paul (Twin Cities)
The dominant MN M&A engine, accounting for the majority of statewide LMM volume and home to all major in-state PE firms and 13 of 15 Fortune 500 HQs. Management-of-companies job concentration ranks #1 nationally (location quotient 1.88). Capital markets include US Bancorp, Ameriprise, and Thrivent. Norwest Equity Partners, Goldner Hawn, ShoreView, Tonka Bay, Spell Capital, Stone Arch Capital, and Yukon Partners all operate from the Twin Cities metro.
Rochester
Anchored by Mayo Clinic (#1 US hospital, state's largest employer) and the $5.6B Destination Medical Center initiative plus a fresh $5B Mayo campus expansion, Rochester's activity skews toward healthcare services roll-ups, life-sciences supply chain, and physician practice consolidation. Alerus Financial's 2025 acquisition of HMN Financial extended Rochester's financial services footprint. National buyers targeting Mayo-adjacent healthcare businesses prioritize Rochester above all other MN metros.
Duluth
Northeastern hub for industrials, Iron Range mining, Great Lakes shipping (Port of Duluth-Superior — largest Great Lakes port by tonnage), and Essentia Health. The ALLETE take-private by CPPIB/Global Infrastructure Partners at $6.3B closed in 2025, signaling institutional appetite for regulated utility and industrial assets in the region. Buyers targeting Iron Range industrial services and maritime logistics concentrate their search in the Duluth metro.
St. Cloud
Manufacturing- and ag-focused central Minnesota hub, home to Granite Partners' long-hold platform strategy and proximity to strong ag-tech, food processing, and contract manufacturing pipelines. St. Cloud's lower cost structure relative to the Twin Cities makes it attractive for value-oriented PE platforms seeking manufacturing roll-up targets without metro valuation premiums. Precision machining, food ingredient processing, and construction products are the primary deal sectors.
How Does Minnesota Compare?
Minnesota M&A benchmarks vs. neighboring states.
Minnesota Deal Landscape 2025–2026
Minnesota M&A volume tracked the broader US rebound in 2025: US deal value rose ~49% YoY to ~$2.3 trillion, and GF Data tracked multiples rising to 7.5x by Q3 2025. MN deal flow leaned heavily toward strategic acquirers — Medtronic, UnitedHealth, Cargill, Ecolab, Solventum, and Cleveland-Cliffs — given the state's unusual density of 15 Fortune 500 HQs. The biggest driver is portfolio reshaping by MN strategics: 3M's Solventum spinoff, Medtronic's MiniMed spinoff (S-1 filed December 19, 2025 at $2.72B revenue), and Cargill protein divestitures are generating both carve-out targets and proceeds for tuck-ins. Aged PE dry powder of $530B nationally has reopened senior debt at 4.0x leverage, accelerating the 50%+ of MN LMM owners aged 55+ who have delayed exit decisions.
Mega-cap carve-outs seeding tuck-in capital
Solventum sold its Purification & Filtration unit to Thermo Fisher for $4.0B (closed September 2, 2025), reducing debt from $8.3B to ~$4.2B and freeing capital for tuck-ins. Medtronic announced the spinoff of its $2.76B-revenue Diabetes business as MiniMed (S-1 filed December 19, 2025 with Goldman Sachs and BofA advising). These corporate actions created several of MN's largest 2025 transactions and are generating downstream supplier M&A as acquirers reconfigure supply chains.
Medtech strategic roll-ups centered on Twin Cities suppliers
Stryker's $4.9B Inari Medical close (February 2025), Boston Scientific's $533M Nalu Medical buy, and Medtronic's $550M Scientia Vascular agreement (February 2026) reflect an $80B+ global medtech M&A year disproportionately benefiting MN-based suppliers. PE platforms Resonetics (Audax/GTCR), Cretex, Phillips-Medisize, Velosity, and Donatelle are active acquirers of catheter and electromechanical assembly shops throughout the Twin Cities metro.
UnitedHealth/Optum behavioral health and home care consolidation
UnitedHealth closed its $3.3B Amedisys acquisition in August 2025, while its MN behavioral-health platform now includes Refresh Mental Health (300+ locations) plus the CARE Counseling tuck-in. PE counterparts include Nystrom & Associates (43 MN clinics), Ellie Mental Health (22 MN clinics), and the Emily Program. Healthcare multiples averaged 8.3x EBITDA in H1 2025 per GF Data — the highest of any tracked sector — creating competitive dynamics in Minnesota's deep healthcare target pool.
Iron Range restructuring and rare-earth optionality
Nippon Steel's closed acquisition of U.S. Steel (June 2025) locks in $500M of Minntac/Keetac capex through 2028. Cleveland-Cliffs idled Hibbing Taconite and Minorca in 2025 (~630 miners), targeting $300M+ in annual savings, then secured Nashwauk mineral leases extending Hibbing's reserve life by 20+ years. CEO Gonçalves disclosed exploratory rare-earth work at two MN/MI sites in Q3 2025, opening a potentially transformative new asset class in the Iron Range for specialty industrial buyers.
Exit Preparation Timeline
A practical roadmap for Minnesota business owners planning an exit.
- Convert from LLC/S-corp to C-corp if QSBS §1202 planning is viable — start the 5-year clock; Minnesota fully conforms to §1202 under Minn. Stat. § 290.01(19), eliminating up to 10.85% state tax on qualifying gain at the post-OBBBA $15M / 10x basis exclusion level.
- Engage a Twin Cities estate planning attorney (Faegre Drinker, Fredrikson & Byron, Dorsey & Whitney) to address the $3M Minnesota estate tax exemption — establish IDGTs, SLATs, or ILITs given non-portability between spouses and the 3-year gift clawback rule.
- Conduct a tax-attribute audit: validate Minnesota R&D credits (10% on first $2M of qualifying MN R&D expenses, 2.5% above $2M under Minn. Stat. § 290.068), NOL carryforwards, and Angel Tax Credit recipient documentation for §382 modeling.
- Begin quality-of-earnings preparation with a regional firm (Baker Tilly, CLA, Boulay, Wipfli) familiar with Minnesota apportionment rules and medtech FDA/QSR financial normalization.
- File a final PTE tax election for tax year 2025 (Minnesota PTE regime expires for tax years beginning after December 31, 2025) by the entity's extended due date; model owner-level MN tax exposure at the 10.85% effective rate (9.85% top bracket + 1% Schedule M1NIIT surtax) for deals closing in 2026+.
- Formalize purchase accounting reserves and clean up sales/use tax nexus exposure across all Minnesota and multistate locations — conduct a post-Wayfair nexus review with a Minnesota DOR-experienced advisor.
- Negotiate and document key-employee retention agreements, non-competes, and rollover equity term sheets — particularly important in Twin Cities medtech where FDA 510(k) holder continuity and ISO 13485 lead auditor retention directly impact deal value.
- Engage an investment banker with a Medical Alley network (Piper Sandler, Cherry Tree, Craig-Hallum, Northborne Partners); prepare CIM and management presentations highlighting FDA regulatory milestones, IP portfolio, and customer concentration metrics.
- Launch confidential marketing to strategic and PE buyers; for medtech, target Medtronic, Boston Scientific, Stryker, Solventum, and PE platforms with medtech theses (Resonetics/Audax, Cretex/Arsenal, JLL Partners, Bain Capital); for food/ag, target Cargill, General Mills, Hormel, Land O'Lakes, and Norwest/Goldner Hawn.
- Conduct a Minnesota DOR compliance review; prepare Form C50 Notice of Business Transfer to obtain successor-liability clearance under Minn. Stat. § 270C.57 — file at least 20 days before closing; if Hennepin or Ramsey County real estate is involved, add the 0.01% Environmental Response Fund surcharge to deed tax modeling.
- Run parallel asset-deal vs. stock-deal tax modeling including 9.8% MN corporate franchise tax on built-in gains (for S-corps within 5-year recognition window), deed tax (0.33% statewide + 0.01% ERF in Hennepin/Ramsey), and sales tax on tangible personal property transfers.
- Distribute teaser, NDA, and CIM; manage indications of interest and select 4–6 finalists for management meetings; for medical device targets, schedule Plymouth/Maple Grove facility tours aligned with buyer regulatory teams.
- File Form C50 with Minnesota DOR; record deed tax via Form DT-2 within 30 days of conveyance; confirm Hennepin/Ramsey ERF surcharge is calculated and paid; obtain DOR clearance letter confirming no successor sales/withholding tax liability.
- Finalize §338(h)(10) or §336(e) elections (if asset-deal tax treatment with stock-deal mechanics) and coordinate with Minnesota corporate franchise tax filings on Form M4 and final-period Form M8/M3 for pass-through entities.
- Negotiate working-capital true-up, escrow (typically 8–12% of EV for medtech given regulatory/product-liability tails), and R&W insurance binder — R&W policies covering Minnesota-registered medical device companies should specifically carve in Minnesota DOR successor-liability and MN estate tax exposure.
- Execute definitive purchase agreement, fund escrow, file Minnesota Form M4 final-period return, coordinate post-closing 1099 reporting for any earnout consideration, and confirm Minnesota Angel Tax Credit recapture conditions have been properly resolved.
Why Minnesota Business Owners Choose Ad Astra
Local market knowledge and national buyer networks — the combination that drives premium outcomes for Minnesota business owners.
Schedule a ConsultationTwin Cities Medtech Corridor Network
Our team maintains active strategic and PE buyer relationships across Minnesota's medtech ecosystem — Medtronic (Fridley/Minneapolis, ~10,000 MN employees), Boston Scientific (Maple Grove, ~7,000), Solventum, Stryker's Plymouth campus, and the Mayo Clinic-anchored device innovation cluster in Rochester. We understand FDA 510(k) transfer mechanics, Minnesota Department of Health distributor licensing, and the ISO 13485/MDSAP audit cadence that drive Class II and III device deal timing — critical differentiators that out-of-state advisors routinely miss.
Minnesota Tax & Estate Planning Depth
Minnesota's 9.8% corporate franchise tax (3rd-highest nationally), 9.85% individual rate plus 1% NIIT surtax above $1M (total 10.85%), and $3M non-portable estate tax exemption require integrated pre-sale planning that most generalist advisors overlook. We coordinate with Twin Cities tax counsel (Boulay, CLA, Baker Tilly, Wipfli, Lurie) to optimize entity structure, the soon-expiring PTE election (expires for tax years after December 31, 2025), and the Minnesota R&D credit (10%/2.5% tiered) years before a transaction.
QSBS §1202 Maximization in a Conforming State
Minnesota fully conforms to IRC §1202 under Minn. Stat. § 290.01(19), meaning QSBS gain excluded federally is also excluded from Minnesota taxable income — eliminating up to 10.85% Minnesota tax on qualifying gain. For Twin Cities medtech, SaaS, and manufacturing C-corps, structuring early-stage capitalization to lock in §1202 status produces full federal and state exclusion on the post-OBBBA $15M / 10x basis cap. We coordinate entity conversions and §1045 rollovers to capture this planning opportunity with proper lead time.
Minnesota Transactional Mechanics Expertise
We routinely manage Minnesota-specific deal infrastructure: Form C50 Notice of Business Transfer filings (≥20 days pre-closing) to extinguish successor liability under Minn. Stat. § 270C.57; deed tax computation and DT-1/DT-2 filings (0.33% statewide plus 0.01% Hennepin/Ramsey Environmental Response Fund); Minnesota sales-tax planning on tangible personal property in asset deals; and final-period Minnesota Form M4/M8/M3 return coordination — friction points that generate last-minute closing delays when advisors without MN transactional experience are at the table.
Minnesota M&A Activity Highlights
Solventum (St. Paul) divested its Purification & Filtration unit to Thermo Fisher Scientific for $4.0B cash, closed September 2, 2025; net proceeds of $3.4B reduced Solventum's debt-to-EBITDA ratio from ~3.8x to ~1.9x post-close.
Ecolab (St. Paul) agreed to acquire CoolIT Systems from KKR/Mubadala for $4.75B — KKR/Mubadala had purchased CoolIT for just $270M in June 2023, representing a 17.5x return in approximately two years, and pivoting Ecolab into AI data-center liquid cooling.
UnitedHealth Group (Minnetonka) closed the acquisition of Amedisys home-health at $3.3B on August 14, 2025, with a $1.1M civil HSR penalty and DOJ-mandated outpatient therapy divestiture to resolve antitrust concerns.
Medtronic filed the MiniMed Diabetes spinoff S-1 on December 19, 2025; MiniMed reported FY25 revenue of $2.72B (up 10.7% YoY) with ~8,000 employees; Scientia Vascular tuck-in announced at $550M in February 2026 as Medtronic accelerated neurovascular platform building.
CPPIB and Global Infrastructure Partners (BlackRock) closed a $6.3B acquisition of Duluth-based ALLETE Inc. following Minnesota Public Utilities Commission approval, representing the largest regulated utility take-private in Upper Midwest history in 2025.
Tax & Deal Structure in Minnesota
Minnesota is among the highest-tax M&A jurisdictions in the US, ranking 44th on the Tax Foundation's 2026 State Competitiveness Index. The state combines a 9.8% corporate franchise tax (3rd-highest nationally), a 9.85% top individual rate with no preferential capital gains treatment, a 1% NIIT surtax above $1M of net investment income, and a non-portable $3M estate tax exemption. These factors make Minnesota M&A planning unusually sensitive to entity structure, QSBS eligibility, PTE election timing, and pre-sale residency and estate planning — rewarding sellers who start 24+ months out.
Corporate Franchise Tax & PTE Election
UnfavorableMinnesota imposes a flat 9.8% corporate franchise tax on C-corp net income (Minn. Stat. ch. 290) — 3rd-highest top corporate rate in the US — plus a 5.8% corporate AMT and a graduated minimum-fee add-on based on MN property/payroll/sales. Pass-through entities could elect Minnesota's PTE tax at 9.85% as a SALT-cap workaround, but the PTE election expires for tax years beginning after December 31, 2025 per the MN DOR's November 21, 2025 update, unless the 2026 legislature extends it. Deals closing in 2026+ must plan for owner-level Minnesota tax with the federal SALT cap raised to $40,000 through 2029 under OBBBA.
Capital Gains Treatment & 1% NIIT Surtax
UnfavorableMinnesota does NOT provide a preferential long-term capital gains rate — all capital gains are taxed as ordinary income at graduated rates up to 9.85% (top bracket roughly $200K+ single / $330K+ MFJ for 2025). Effective for tax years beginning after December 31, 2023, Minnesota added a 1% surtax on net investment income exceeding $1 million (Schedule M1NIIT), bringing the effective top marginal rate on large investment gains to 10.85%. A founder selling for a $10M+ gain triggers both the 9.85% top bracket and the 1% surtax on gain above $1M; installment sales, CRTs, and pre-sale residency changes are common mitigation strategies, but Minnesota aggressively scrutinizes residency using a 26-factor domicile test.
QSBS / Section 1202 Conformity
FavorableMinnesota fully conforms to IRC §1202 at both the corporate and individual level via Minn. Stat. § 290.01(19), meaning gain excluded federally on Qualified Small Business Stock is also excluded from Minnesota taxable income. Under post-OBBBA rules (for stock issued after July 4, 2025), the exclusion cap rises to $15M or 10x basis. Minnesota residents can stack the federal exclusion with full state exclusion — saving up to 10.85% Minnesota tax on excluded gain. For Twin Cities medtech, SaaS, and manufacturing C-corps, properly structured early-stage QSBS planning is one of the most valuable Minnesota planning tools available.
Asset vs. Stock Sale: Deed Tax, Sales Tax & Successor Liability
NeutralMinnesota imposes a deed/transfer tax of 0.33% (Minn. Stat. ch. 287) on real property transfers, with an additional 0.01% Environmental Response Fund tax in Hennepin and Ramsey counties. Equipment and certain software transferred in an asset sale can attract Minnesota's 6.875% state sales tax (8.13% combined average) unless an occasional-sale exemption applies. Critically, Minn. Stat. § 270C.57 imposes successor liability on bulk asset transfer buyers for seller's unpaid sales, withholding, and petroleum taxes — buyers must file Form C50 at least 20 days before closing and obtain DOR clearance or risk personal liability up to the purchase price.
Minnesota Estate Tax with $3M Exemption
UnfavorableMinnesota is one of ~12 states with a stand-alone estate tax: a $3,000,000 per-person exemption (NOT indexed for inflation, NOT portable between spouses), with graduated rates from 13% to 16% (top rate above $10.1M of taxable estate). Minnesota also claws back taxable gifts made within 3 years of death. A Qualified Small Business and Farm Property Deduction (Schedule M706Q) of up to $2,000,000 brings the effective shelter to $5M for qualifying estates — but strict rules apply: ≤$10M gross sales, 3-year pre-death ownership, and a 16% recapture tax on premature disposition. Pre-sale gifting to grantor trusts, IDGTs, and ILITs are critical for $3M+ estates.
Minnesota Angel Tax Credit & R&D Credit
FavorableMinnesota's Angel Investment Tax Credit (administered by DEED) provides a refundable 25% credit to certified accredited investors in qualifying high-tech or medtech MN small businesses, capped at $125,000 per individual annually; minimum qualifying investment is $10,000. Minnesota also offers an R&D Credit of 10% on the first $2M of qualifying Minnesota R&D expenses and 2.5% on amounts above $2M (Minn. Stat. § 290.068). For Twin Cities medtech and software sellers, undocumented R&D credit positions are a frequent due-diligence finding — properly substantiated credits can enhance valuation by demonstrating Minnesota tax-attribute carryforwards available to acquirers.
Representative Transaction
Illustrative model only. Not representative of a current or past Ad Astra Equity client engagement. Details modified to protect client confidentiality. Ranges are representative.
The Business
Class II medical device manufacturer, Plymouth/Maple Grove MN — single-use minimally invasive surgical instruments distributed to US hospitals and ambulatory surgery centers
Key Metrics
Revenue
$45M–$65MEBITDA
$11M–$16MMargin
24%–27% EBITDA; 62%–68% gross marginRetention
Top-10 customer concentration ~35%; 6–9 active FDA 510(k) clearancesThe Challenge
Two intertwined risks dominated diligence. Key-person risk: the founder/CEO was the named regulatory contact on most 510(k) submissions and held undocumented institutional knowledge of supplier validation files — buyers required a 24-month transition employment agreement plus a meaningful earnout. Minnesota-specific regulatory and tax risk: the company had received Minnesota Angel Tax Credit-certified investments in three prior rounds (creating recapture scrutiny), had unsubstantiated Minnesota R&D credits claimed at the 10% tier on roughly $1.8M of design-history-file labor, and operated under a Minnesota Department of Health medical device distributor registration requiring transfer notification. The founder's personal estate also exceeded the $3M Minnesota estate tax threshold without utilization of the $2M Qualified Small Business Property Deduction.
The Process
- 1Engaged 18 strategic medtech acquirers and 6 healthcare PE platforms under NDA, targeting Medtronic, Boston Scientific, Teleflex, Integra LifeSciences, and Twin Cities-based PE firms; conducted a 14-week marketing process with management presentations in Plymouth and virtual sessions with Rochester-based clinical advisors.
- 2Negotiated 5 written IOIs and 3 final LOIs, leveraging competitive tension between strategic and PE bidders; required all bidders to address §338(h)(10) election mechanics and Minnesota Form C50 predecessor-liability clearance as conditions of the process.
- 3Executed confirmatory diligence including QofE, FDA regulatory transfer planning, MN tax review and Form C50 DOR filing, R&W insurance binding with Minnesota-specific carve-in of Angel Tax Credit recapture conditions, and MN Department of Health distributor registration transfer coordination.
- 4Closed within 70 days of LOI signing; coordinated deed tax recording via Form DT-2, final-period Minnesota Form M4 return, and structured earnout consideration to align with FDA 510(k) line extensions and revenue thresholds over 24 months post-close.
Deal Outcome
Enterprise Value
9.0x–11.0x trailing EBITDA
Premium vs. Market
18%–25% above initial IOI midpoint
Time to Close
8–10 months
Seller Rollover
75%–80% cash at close, 10%–15% rollover equity, 5%–10% performance earnout tied to 510(k) line extensions; 10% indemnity escrow backed by R&W insurance
Key Lessons
- QSBS §1202 planning would have been transformative — the company had operated as an S-corp for its first 6 years; earlier C-corp conversion (with Minnesota's full §1202 conformity) could have eliminated up to 10.85% Minnesota tax plus federal tax on a substantial portion of the founder's gain, worth $1.5M–$2.5M in after-tax proceeds.
- Pre-marketing review of Minnesota Angel Tax Credit recapture conditions and substantiation of the 10%/2.5% R&D credit tiers avoided a last-minute purchase-price holdback; MN buyers are increasingly sophisticated about tax-attribute diligence and will discount undocumented credit positions dollar-for-dollar.
- Front-loading FDA regulatory transfer planning (510(k) holder transfers, MDH distributor registration, ISO 13485 transition) prevented post-closing supply disruption and protected the earnout tied to product-line extensions.
Frequently Asked Questions
Common questions about selling a business in Minnesota.
Still have questions? Let's talkAlso serving neighboring states
Ready to Explore Your Minnesota Exit?
Schedule a confidential conversation to discuss your Minnesota business, your goals, and how our local expertise and national buyer network can maximize your outcome.